EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial

George Kypriotakis, Paul M Cinciripini, Charles E Green, David Lawrence, Robert M Anthenelli, Jennifer A Minnix, Diane Beneventi, Chad Morris, Maher Karam-Hage, Janice A Blalock

American Journal of Psychiatry · 2025

DOI: 10.1176/appi.ajp.20230855 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Psychiatry, 2025. Verfasst von George Kypriotakis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston (Kypriotakis, Cinciripini, Minnix, Beneventi, Karam-Hage, Bl…. Hauptthemen laut MEDLINE: Varenicline, Bupropion, Major Depressive Disorder, Smoking Cessation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD). METHODS: This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling. The primary safety outcome was occurrence of one or more moderate to severe neuropsychiatric adverse events. Efficacy was assessed as biochemically verified continuous abstinence during weeks 9-12. RESULTS: Among all 6,653 participants, the risk of neuropsychiatric adverse events did not differ by medication within the past-MDD, current-MDD, or nonpsychiatric cohorts. The MDD cohorts had higher risk difference (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VareniclineBupropionMajor Depressive DisorderSmoking CessationTobacco Use Cessation DevicesSmoking Cessation AgentsSmokingHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedYoung AdultAdolescentAgedTreatment Outcome

Stichwörter der Autor:innen

Drug/Psychotherapy CombinationMajor Depressive DisorderNicotineSubstance-Related and Addictive Disorders

Substanzen

VareniclineBupropionSmoking Cessation Agents

Autor:innen und Institutionen

  • Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston (Kypriotakis, Cinciripini, Minnix, Beneventi, Karam-Hage, Blalock); Department of Pediatrics, University of Texas Medical School a…

Zitieren

APA

Kypriotakis, G., Cinciripini, P. M., Green, C. E., Lawrence, D., Anthenelli, R. M., Minnix, J. A., Beneventi, D., Morris, C., Karam-Hage, M., & Blalock, J. A. (2025). Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20230855

Vancouver

Kypriotakis G, Cinciripini PM, Green CE, Lawrence D, Anthenelli RM, Minnix JA, et al. Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Psychiatry. 2025. doi:10.1176/appi.ajp.20230855

BibTeX
@article{Kypriotakis2025,
  author = {Kypriotakis, George and Cinciripini, Paul M and Green, Charles E and Lawrence, David and Anthenelli, Robert M and Minnix, Jennifer A and Beneventi, Diane and Morris, Chad and Karam-Hage, Maher and Blalock, Janice A},
  title = {Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial},
  journal = {American Journal of Psychiatry},
  year = {2025},
  doi = {10.1176/appi.ajp.20230855}
}
Kostenlos starten →